JAMA Oncol 2020 Apr 16
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
Related Questions
New answer by Medical Oncologist at Mayo Clinic (August 6, 2021)
I agree with the above. Of course, quality data (in the form of RCTs) are lacking when it comes to retreatment with PRRT (rPRRT). We have typically selected patients where oth...
Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusi...
New answer by Medical Oncologist at Mayo Clinic (December 8, 2020)
This is a complicated answer (especially for me as a medical oncologist...). The main factors to consider are the tumor grade, tumor behavior, extent and location of metastase...